Cargando…
Treatment of children under 4 years of age with medulloblastoma and ependymoma in the HIT2000/HIT-REZ 2005 trials: Neuropsychological outcome 5 years after treatment
Young children with brain tumours are at high risk of developing treatment-related sequelae. We aimed to assess neuropsychological outcomes 5 years after treatment. This cross-sectional study included children under 4 years of age with medulloblastoma (MB) or ependymoma (EP) enrolled in the German b...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6977734/ https://www.ncbi.nlm.nih.gov/pubmed/31971950 http://dx.doi.org/10.1371/journal.pone.0227693 |
_version_ | 1783490576048455680 |
---|---|
author | Ottensmeier, Holger Schlegel, Paul G. Eyrich, Matthias Wolff, Johannes E. Juhnke, Björn-Ole von Hoff, Katja Frahsek, Stefanie Schmidt, Rene Faldum, Andreas Fleischhack, Gudrun von Bueren, Andre Friedrich, Carsten Resch, Anika Warmuth-Metz, Monika Krauss, Jürgen Kortmann, Rolf D. Bode, Udo Kühl, Joachim Rutkowski, Stefan |
author_facet | Ottensmeier, Holger Schlegel, Paul G. Eyrich, Matthias Wolff, Johannes E. Juhnke, Björn-Ole von Hoff, Katja Frahsek, Stefanie Schmidt, Rene Faldum, Andreas Fleischhack, Gudrun von Bueren, Andre Friedrich, Carsten Resch, Anika Warmuth-Metz, Monika Krauss, Jürgen Kortmann, Rolf D. Bode, Udo Kühl, Joachim Rutkowski, Stefan |
author_sort | Ottensmeier, Holger |
collection | PubMed |
description | Young children with brain tumours are at high risk of developing treatment-related sequelae. We aimed to assess neuropsychological outcomes 5 years after treatment. This cross-sectional study included children under 4 years of age with medulloblastoma (MB) or ependymoma (EP) enrolled in the German brain tumour trials HIT2000 and HIT-REZ2005. Testing was performed using the validated Wuerzburg Intelligence Diagnostics (WUEP-D), which includes Kaufman-Assessment-Battery, Coloured Progressive Matrices, Visual-Motor Integration, finger tapping “Speed”, and the Continuous Performance Test. Of 104 patients in 47 centres, 72 were eligible for analyses. We assessed whether IQ was impacted by disease extent, disease location, patient age, gender, age at surgery, and treatment (chemotherapy with our without craniospinal irradiation [CSI] or local radiotherapy [LRT]). Median age at surgery was 2.3 years. Testing was performed at a median of 4.9 years after surgery. Patients with infratentorial EPs (treated with LRT) scored highest in fluid intelligence (CPM 100.9±16.9, mean±SD); second best scores were achieved by patients with MB without metastasis treated with chemotherapy alone (CPM 93.9±13.2), followed by patients with supratentorial EPs treated with LRT. In contrast, lowest scores were achieved by patients that received chemotherapy and CSI, which included children with metastasised MB and those with relapsed MB M0 (CPM 71.7±8.0 and 73.2±21.8, respectively). Fine motor skills were reduced in all groups. Multivariable analysis revealed that type of treatment had an impact on IQ, but essentially not age at surgery, time since surgery or gender. Our results confirm previous reports on the detrimental effects of CSI in a larger cohort of children. Comparable IQ scores in children with MB treated only with chemotherapy and in children with EP suggest that this treatment strategy represents an attractive option for children who have a high chance to avoid application of CSI. Longitudinal follow-up examinations are warranted to assess long-term neuropsychological outcomes. |
format | Online Article Text |
id | pubmed-6977734 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-69777342020-02-07 Treatment of children under 4 years of age with medulloblastoma and ependymoma in the HIT2000/HIT-REZ 2005 trials: Neuropsychological outcome 5 years after treatment Ottensmeier, Holger Schlegel, Paul G. Eyrich, Matthias Wolff, Johannes E. Juhnke, Björn-Ole von Hoff, Katja Frahsek, Stefanie Schmidt, Rene Faldum, Andreas Fleischhack, Gudrun von Bueren, Andre Friedrich, Carsten Resch, Anika Warmuth-Metz, Monika Krauss, Jürgen Kortmann, Rolf D. Bode, Udo Kühl, Joachim Rutkowski, Stefan PLoS One Research Article Young children with brain tumours are at high risk of developing treatment-related sequelae. We aimed to assess neuropsychological outcomes 5 years after treatment. This cross-sectional study included children under 4 years of age with medulloblastoma (MB) or ependymoma (EP) enrolled in the German brain tumour trials HIT2000 and HIT-REZ2005. Testing was performed using the validated Wuerzburg Intelligence Diagnostics (WUEP-D), which includes Kaufman-Assessment-Battery, Coloured Progressive Matrices, Visual-Motor Integration, finger tapping “Speed”, and the Continuous Performance Test. Of 104 patients in 47 centres, 72 were eligible for analyses. We assessed whether IQ was impacted by disease extent, disease location, patient age, gender, age at surgery, and treatment (chemotherapy with our without craniospinal irradiation [CSI] or local radiotherapy [LRT]). Median age at surgery was 2.3 years. Testing was performed at a median of 4.9 years after surgery. Patients with infratentorial EPs (treated with LRT) scored highest in fluid intelligence (CPM 100.9±16.9, mean±SD); second best scores were achieved by patients with MB without metastasis treated with chemotherapy alone (CPM 93.9±13.2), followed by patients with supratentorial EPs treated with LRT. In contrast, lowest scores were achieved by patients that received chemotherapy and CSI, which included children with metastasised MB and those with relapsed MB M0 (CPM 71.7±8.0 and 73.2±21.8, respectively). Fine motor skills were reduced in all groups. Multivariable analysis revealed that type of treatment had an impact on IQ, but essentially not age at surgery, time since surgery or gender. Our results confirm previous reports on the detrimental effects of CSI in a larger cohort of children. Comparable IQ scores in children with MB treated only with chemotherapy and in children with EP suggest that this treatment strategy represents an attractive option for children who have a high chance to avoid application of CSI. Longitudinal follow-up examinations are warranted to assess long-term neuropsychological outcomes. Public Library of Science 2020-01-23 /pmc/articles/PMC6977734/ /pubmed/31971950 http://dx.doi.org/10.1371/journal.pone.0227693 Text en © 2020 Ottensmeier et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Ottensmeier, Holger Schlegel, Paul G. Eyrich, Matthias Wolff, Johannes E. Juhnke, Björn-Ole von Hoff, Katja Frahsek, Stefanie Schmidt, Rene Faldum, Andreas Fleischhack, Gudrun von Bueren, Andre Friedrich, Carsten Resch, Anika Warmuth-Metz, Monika Krauss, Jürgen Kortmann, Rolf D. Bode, Udo Kühl, Joachim Rutkowski, Stefan Treatment of children under 4 years of age with medulloblastoma and ependymoma in the HIT2000/HIT-REZ 2005 trials: Neuropsychological outcome 5 years after treatment |
title | Treatment of children under 4 years of age with medulloblastoma and ependymoma in the HIT2000/HIT-REZ 2005 trials: Neuropsychological outcome 5 years after treatment |
title_full | Treatment of children under 4 years of age with medulloblastoma and ependymoma in the HIT2000/HIT-REZ 2005 trials: Neuropsychological outcome 5 years after treatment |
title_fullStr | Treatment of children under 4 years of age with medulloblastoma and ependymoma in the HIT2000/HIT-REZ 2005 trials: Neuropsychological outcome 5 years after treatment |
title_full_unstemmed | Treatment of children under 4 years of age with medulloblastoma and ependymoma in the HIT2000/HIT-REZ 2005 trials: Neuropsychological outcome 5 years after treatment |
title_short | Treatment of children under 4 years of age with medulloblastoma and ependymoma in the HIT2000/HIT-REZ 2005 trials: Neuropsychological outcome 5 years after treatment |
title_sort | treatment of children under 4 years of age with medulloblastoma and ependymoma in the hit2000/hit-rez 2005 trials: neuropsychological outcome 5 years after treatment |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6977734/ https://www.ncbi.nlm.nih.gov/pubmed/31971950 http://dx.doi.org/10.1371/journal.pone.0227693 |
work_keys_str_mv | AT ottensmeierholger treatmentofchildrenunder4yearsofagewithmedulloblastomaandependymomainthehit2000hitrez2005trialsneuropsychologicaloutcome5yearsaftertreatment AT schlegelpaulg treatmentofchildrenunder4yearsofagewithmedulloblastomaandependymomainthehit2000hitrez2005trialsneuropsychologicaloutcome5yearsaftertreatment AT eyrichmatthias treatmentofchildrenunder4yearsofagewithmedulloblastomaandependymomainthehit2000hitrez2005trialsneuropsychologicaloutcome5yearsaftertreatment AT wolffjohannese treatmentofchildrenunder4yearsofagewithmedulloblastomaandependymomainthehit2000hitrez2005trialsneuropsychologicaloutcome5yearsaftertreatment AT juhnkebjornole treatmentofchildrenunder4yearsofagewithmedulloblastomaandependymomainthehit2000hitrez2005trialsneuropsychologicaloutcome5yearsaftertreatment AT vonhoffkatja treatmentofchildrenunder4yearsofagewithmedulloblastomaandependymomainthehit2000hitrez2005trialsneuropsychologicaloutcome5yearsaftertreatment AT frahsekstefanie treatmentofchildrenunder4yearsofagewithmedulloblastomaandependymomainthehit2000hitrez2005trialsneuropsychologicaloutcome5yearsaftertreatment AT schmidtrene treatmentofchildrenunder4yearsofagewithmedulloblastomaandependymomainthehit2000hitrez2005trialsneuropsychologicaloutcome5yearsaftertreatment AT faldumandreas treatmentofchildrenunder4yearsofagewithmedulloblastomaandependymomainthehit2000hitrez2005trialsneuropsychologicaloutcome5yearsaftertreatment AT fleischhackgudrun treatmentofchildrenunder4yearsofagewithmedulloblastomaandependymomainthehit2000hitrez2005trialsneuropsychologicaloutcome5yearsaftertreatment AT vonbuerenandre treatmentofchildrenunder4yearsofagewithmedulloblastomaandependymomainthehit2000hitrez2005trialsneuropsychologicaloutcome5yearsaftertreatment AT friedrichcarsten treatmentofchildrenunder4yearsofagewithmedulloblastomaandependymomainthehit2000hitrez2005trialsneuropsychologicaloutcome5yearsaftertreatment AT reschanika treatmentofchildrenunder4yearsofagewithmedulloblastomaandependymomainthehit2000hitrez2005trialsneuropsychologicaloutcome5yearsaftertreatment AT warmuthmetzmonika treatmentofchildrenunder4yearsofagewithmedulloblastomaandependymomainthehit2000hitrez2005trialsneuropsychologicaloutcome5yearsaftertreatment AT kraussjurgen treatmentofchildrenunder4yearsofagewithmedulloblastomaandependymomainthehit2000hitrez2005trialsneuropsychologicaloutcome5yearsaftertreatment AT kortmannrolfd treatmentofchildrenunder4yearsofagewithmedulloblastomaandependymomainthehit2000hitrez2005trialsneuropsychologicaloutcome5yearsaftertreatment AT bodeudo treatmentofchildrenunder4yearsofagewithmedulloblastomaandependymomainthehit2000hitrez2005trialsneuropsychologicaloutcome5yearsaftertreatment AT kuhljoachim treatmentofchildrenunder4yearsofagewithmedulloblastomaandependymomainthehit2000hitrez2005trialsneuropsychologicaloutcome5yearsaftertreatment AT rutkowskistefan treatmentofchildrenunder4yearsofagewithmedulloblastomaandependymomainthehit2000hitrez2005trialsneuropsychologicaloutcome5yearsaftertreatment |